Imported ≠ irrelevant. Hong Kong has logged 16+ imported chikungunya cases in 2025 (all imported). That’s already above typical 2016–2019 levels (1–11/yr). These imports act as an indirect diagnostic of intense regional circulation (thousands of local cases in Asia this year, esp. India and Indonesia).
Why it matters? the city’s main competent vector Aedes albopictus is widespread (while Aedes aegypti is not present), and authorities actively track mosquito density with the gravidtrap index. With multiple imports, CHP flags a risk of secondary local transmission in suitable conditions.
Context for travelers & clinicians: chikungunya vaccines are available in some jurisdictions (e.g., FDA-approved Ixchiq; EU-authorised), but not locally registered in Hong Kong; prevention still hinges on bite avoidance and source reduction.
